Bae Seongman, Kim Taeeun, Kim Min-Chul, Chong Yong Pil, Kim Sung-Han, Sung Heungsup, Lim Young-Suk, Lee Sang-Oh, Kim Mi-Na, Kim Yang Soo, Woo Jun Hee, Choi Sang-Ho
Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
BMC Infect Dis. 2016 Jun 7;16:252. doi: 10.1186/s12879-016-1595-y.
Enterobacter species are important nosocomial pathogens, and there is growing concern about their ability to develop resistance during antimicrobial therapy. However, few data are available on the clinical characteristics and outcomes of Enterobacter spontaneous bacterial peritonitis (SBP).
We retrospectively identified all patients with SBP caused by Enterobacter species admitted to a tertiary care hospital between January 1997 and December 2013. Each case was age- and sex-matched with four patients with Escherichia coli SBP.
A total of 32 cases with Enterobacter SBP and 128 controls with E. coli SBP were included. Twenty-one (65.6 %) cases and 111 (86.7 %) controls had Child-Pugh class C (P = 0.006). Cases were significantly more likely to have hepatocellular carcinoma (65.6 % vs. 37.5 %, P = 0.004) and upper gastrointestinal bleeding (28.1 % vs. 9.4 %, P = 0.005). The initial response to empirical therapy (81.3 % vs. 81.2 %, P = 0.995) and the 30-day mortality (37.5 % vs. 28.9 %, P = 0.35) were not significantly different between the groups. Drug resistance emerged in one case and in no controls (4.3 % [1/23] vs. 0 % [0/98], P = 0.19).
Compared with E. coli SBP, patients with Enterobacter SBP more frequently had hepatocellular carcinoma and upper gastrointestinal bleeding, yet clinical outcomes were comparable. Development of resistance during third-generation cephalosporin therapy was infrequent in patients with Enterobacter SBP.
肠杆菌属是重要的医院感染病原体,人们越来越关注其在抗菌治疗过程中产生耐药性的能力。然而,关于肠杆菌属自发性细菌性腹膜炎(SBP)的临床特征和预后的数据却很少。
我们回顾性地确定了1997年1月至2013年12月期间入住一家三级医疗医院的所有由肠杆菌属引起的SBP患者。每个病例在年龄和性别上与4例大肠杆菌SBP患者进行匹配。
共纳入32例肠杆菌属SBP患者和128例大肠杆菌SBP对照患者。21例(65.6%)病例和111例(86.7%)对照患者为Child-Pugh C级(P = 0.006)。病例组肝细胞癌的发生率显著更高(65.6%对37.5%,P = 0.004),上消化道出血的发生率也显著更高(28.1%对9.4%,P = 0.005)。两组间经验性治疗的初始反应(81.3%对81.2%,P = 0.995)和30天死亡率(37.5%对28.9%,P = 0.35)无显著差异。1例病例出现耐药,对照中无耐药发生(4.3%[1/23]对0%[0/98],P = 0.19)。
与大肠杆菌SBP相比,肠杆菌属SBP患者肝细胞癌和上消化道出血更为常见,但临床预后相当。肠杆菌属SBP患者在第三代头孢菌素治疗期间耐药的发生并不常见。